Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Tocagen (TOCA) Stock Price
News headlines about Tocagen (NASDAQ:TOCA) have trended somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tocagen earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.4552698302057 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Are Tocagen Inc’s (TOCA) Interest Costs Too High? (finance.yahoo.com)
- Tocagen to Report Third Quarter 2017 Financial Results on Wednesday, November 8 (finance.yahoo.com)
- TOCAGEN INC (TOCA) Scheduled to Post Quarterly Earnings on Wednesday (americanbankingnews.com)
- Financial Review: Applied Genetic Technologies Corporation (AGTC) versus Tocagen (TOCA) (americanbankingnews.com)
- Robust survival sends Tocagen’s Toca-511/FC from phase I to pivotal trial for brain cancer (bioworld.com)
Tocagen (NASDAQ:TOCA) traded up $0.10 during trading on Monday, reaching $10.86. 145,088 shares of the company traded hands, compared to its average volume of 306,449. Tocagen has a one year low of $8.60 and a one year high of $17.95. The company has a quick ratio of 7.20, a current ratio of 7.20 and a debt-to-equity ratio of 0.08.
Tocagen (NASDAQ:TOCA) last released its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.04). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. analysts forecast that Tocagen will post -2.85 EPS for the current year.
TOCA has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Tocagen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Stifel Nicolaus reissued a “buy” rating and set a $24.00 price target on shares of Tocagen in a research note on Tuesday, July 25th.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.